Most encouraging, some KATP channel activators and antagonists have shown good results for treating KATP channel subunit mutation-related diseases, such as Cantú syndrome, congenital hyperinsulinism (CHI), neonatal diabetes mellitus (NDM), developmental delay epilepsy and neonatal diabetes (DEND) and ABCC9-related intellectual disability myopathy Syndrome (AIMS) (Demirbilek et al., 2019; Martin et al., 2020; McClenaghan et al., 2020). The gene discussed is ABCC9; the disease is congenital isolated hyperinsulinism.